The FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) has voted this week in favor of approving buprenorphine subnormal implant (Probuphine, Titan).
The rod-shaped implant can provide up to six months of sustained delivery of the opioid partial agonist buprenorphine when four rods are inserted subdermally, according to the PDAC. The drug is intended as a maintenance treatment for stable, opioid-dependent patients receiving 8 mg or less of buprenorphine per